



KANEKA

The Dreamology Company
—Make your dreams come true—

(Stock Code: 4118)

To Our Shareholders

**Interim Report for
the 97th Business Period**

From April 1 to September 30, 2020

KANEKA CORPORATION

KANEKA thinks “Wellness First”.



Kaneka brings the environment to its ideal state,
develops its business in a “wellness-first” direction,
energizes people,
adds vibrancy to business,
and helps build a happier society.

To make the world more wellness-first.
Kaneka takes an innovative approach to science,
and seeks to fulfill people’s dreams by offering a wide variety of solutions.

Sustainable Solutions for an Evolving World.

Message from the President



President



Minoru Tanaka

To our valued shareholders, Thank you for your continued support and interest in Kaneka Group.

President and Representative Director Minoru Tanaka, who was appointed in April 2020, reviews the business performance for the first half, the forecast, and the new medium-term management plan.

Q How did you feel about your appointment as president in April?

A When I was approached about the appointment, the Company’s earnings were struggling, and my first thought was that I would be taking on a tremendous responsibility. At the same time, I was felt a strong sense of mission—that I must do something to close the gap and realize the 2020 goals that we had laid out under the long-term management vision,

“Declaration of Kaneka United for the future,” which we formulated when I was General Manager of the Corporate Planning Division. Partly because of the impact of the COVID-19 pandemic, my term has started in rough conditions, but I intend to contribute as best as I can as the culmination of my life in the Company.

Q Could you review the first half and give your forecast for the second half and onward?

A Global economic activity has been hit hard by the COVID-19 pandemic, giving rise to a rapid paradigm shift in society, along with a variety of changes in people’s values. The global economy rebounded from the serious downturn in the first quarter (April-June 2020; “1Q”) and showed increasingly strong signs of recovery in various industries in the second quarter (July-September 2020; “2Q”), primarily in China and the U.S. From October onward, the pace of recovery is expected to increase overall, despite some lingering uncertainty about factors such as the impact of a second wave of COVID-19 in Europe and the U.S.

Under the current conditions, the Group’s first-half performance saw decreases in both sales and profits year on year, with net sales of ¥266.7 billion and operating income of ¥7.0 billion. However, the foundation business group (Vinyls and Chlor-Alkali, Performance Polymers (MOD), Performance Polymers (MS), Foam & Residential Techs, Performance Fibers, and Foods & Agris), which was heavily impacted by the COVID-19 crisis in 1Q, has steadily improved from 2Q onward, owing to progress on an improvement in production in step with the resumption of global economic activity. The

Company now sees a clear path for the foundation business group to return to a trajectory for additional growth beyond COVID-19. The highly profitable leading-edge business group (E & I Technology, PV & Energy management, Medical, Pharma, Supplemental Nutrition, and Agricultural production support), which has an expanding range of growth opportunities amid the current paradigm shift, continues to achieve steady growth. As a result, we anticipate stronger momentum from October onward, shifting our performance from an improvement to a stage of resurgent growth. Looking ahead the dramatic paradigm shift caused by the coronavirus shock, the Company is working to improve productivity and create new business value by applying a “select and concentrate” strategy to Research & Business (R&B) initiatives and by promoting digital transformation (DX) of back office departments and other areas. Meanwhile, the Company is working to implement rigorous cost rationalization, including operating expenses. The Company will work to accelerate the transformation of the business portfolio by striving to realize “Smart Work,” a Company-wide initiative to maximize productivity.

Q A new medium-term management plan was announced in October. Could you give an overview of the plan?

A Under the new medium-term management plan, we will further accelerate the portfolio transformation. While striving to strengthen our corporate constitution amid COVID-19, we will prioritize allocation of management resources to leading-edge businesses such as E & I, PV, Medical, Pharma and Supplement where growth opportunities are expanding amid the paradigm change, as well as new large-scale businesses such as PHBH, OLED, and regenerative medicine and cell

therapy. Kaneka has diverse businesses, diverse technologies, and a multitude of Only One and Global No.1 technologies and products. While firmly positioning these strengths as our axis, we will strive to also make the most of external resources such as open innovation and M&A to create high added value.

We will make leading-edge businesses a core pillar driving Kaneka's business performance. Focusing on

infectious diseases, in Pharma, we will further expand facilities at Kaneka Eurogentec S.A. ("KEGT"), where orders for COVID-19 vaccines and treatments are growing rapidly. In Medical business, we will increase the production capacity of our plant in Vietnam to meet robust demand that is globally growing, while aiming to expand the scope of our operations in areas that can help address COVID-19, such as testing and diagnostics and medical devices. As a result, we will greatly expand intervention business.

The COVID-19 pandemic is speeding up the sophistication of digital and telecommunications all at once. With social implementation of 5G, EVs, and CASE advancing, our goal in E & I is to grasp market trends and develop distinctive materials that contribute to the digital society and expand business in the polyimide products, optical film, optoelectronics fields.

In new large-scale businesses, especially PHBH, we need to accelerate social implementation, so are working with global brand holders to develop applications. We plan to build a commercial production plant and hope to be able to announce it at the earliest possible time.

Meanwhile, in the foundation businesses, we will build a strong platform to support the management base. In Vinyls and Chlor-Alkali and Performance Polymers (MOD, MS), where the COVID-19 pandemic has temporarily eliminated demand globally, we will focus on restoring the profitability of





highly-unique, high-added value special PVC and modifiers. Right now, demand is rapidly recovering in the Materials Solutions Unit, with especially sharp growth in demand for paste PVC for disposable gloves in connection with COVID-19.

We are forecasting net sales of ¥700 billion and operating income of ¥53 billion in fiscal 2022 as a result of these measures. The share of leading-edge and new large-scale businesses in overall operating income will increase from 25% in fiscal 2019 to 50% in fiscal 2022, dramatically transforming the business portfolio.

And finally, regarding the interim dividend, we have decided on ¥50 per share. I thank you very much for your continued support.



Highlights of consolidated business performance



Business Performance by Segment

Earthology Chemical Solution / Create a comfortable and sustainable living environment

Material Solutions Unit

Material Value Creator

To support the advancement of life and the environment by drawing out the richness of the materials

In the **Vinyls and Chlor-Alkali** business, in 2Q, exports of general PVC resins increased sharply to India and China after lockdowns were lifted. Shipments of chlorinated PVC (CPVC) also began. Paste PVC for hygiene gloves performed well, with the Malaysia plant operating at full capacity. In 2Q, profits increased year on year.

In the **Performance Polymers** business, demand for modifiers recovered in Europe, the U.S. and Asia as economic activity restarted. Since the latter half of 2Q, sales volume has returned to the previous year's level.

Demand for modified silicone polymers recovered in Europe and the U.S., in addition to demand for construction applications in China. In 2Q, performance returned to the previous year's level.

In Kaneka Biodegradable Polymer PHBH, conclusive work for productivity increases and cost reductions continue to proceed toward a decision on constructing a plant with a 20,000-t production capacity.

The Material Solutions Unit recorded lower sales and profits than previous year.

Quality of Life Solutions Unit

Quality of Life Pathfinder

To produce the leading edge of the enhancement of the quality of life through the power of materials

In the **Performance Fibers** business, demand for hair accessories and flame retardance materials for Africa and the U.S. slumped due to the COVID-19 impact in 1Q. But demand for hair accessories in Africa have been recovering every month since July. There have been delays in the recovery of demand for flame retardance materials and pile for apparel applications.

In the **Foam & Residential Techs** business, spreads were maintained for expanded polystyrene resin and extruded polystyrene foam boards despite sluggish domestic demand. Polyolefin foam products for automobiles, which had been falling behind, follow a recovery trend.

In the **PV & Energy management** business, sales of high-efficiency photovoltaic module products for residences were firm due to an increase in the adoption rate.

In the **E & I Technology** business, in 2Q, the shipments of PIXEO products recorded an all-time high. This is because demand for smartphones and materials for tablets and laptop PCs was strong due to increasing remote work population in connection with the COVID-19 crisis. Sales increased for 5G products. New product development is also progressing steadily.

The Quality of Life Solutions Unit recorded lower sales and profits than previous year.

Active Human Life Solution / Supporting energetic and healthy living

Health Care Solutions Unit

Medical Edge Explorer

To create a world in where advanced medical means are available to as many people as possible

In the **Medical** business, the domestic and overseas markets both expanded. Coils for embolization of brain aneurysms, a new product, performed well. Sales of this new product began in the U.S. in September and have been contributing to earnings growth. Sales of a new blood purification system for treatment of arteriosclerosis obliterans (ASO) are scheduled for 2021.

In the **Pharma** business, earnings rose sharply year on year, due to factors such as the start of the supply of active pharmaceutical ingredients for Avigan® Tablet and Kaneka Eurogentec S.A.'s reagents for PCR tests. Kaneka Eurogentec S.A. has received a growing number of inquiries from major global pharmaceutical companies, beginning with production of vaccine intermediates for AnGes, Inc. New facilities for enhanced biologics capacity started operation in October and will make a positive contribution to earnings. Kaneka Eurogentec S.A. is currently considering implementing the next phase of capacity increase at an early stage.

The Health Care Solutions Unit recorded higher sales and profits than previous year.

Nutrition Solutions Unit


Nutrition Value Chain Innovator

To re-innovate food and health

In the **Supplemental Nutrition** business, strong sales were posted for the active form of coenzyme Q10 (Kaneka QH) due to increasing awareness of immunity enhancement in the U.S. The Group plans to start selling lactic acid bacteria in Japan following the U.S. from autumn 2020. These lactic acid bacteria have proven effective in improving the intestinal environment.

In the **Food & Agris** business, sales of spice products were strong due to an increase in home meals. Although demand for bread and confectionery is on a recovery track, the pace of recovery has been slow due to the lack of inbound tourism. The Group opened an online shop for Kaneka Group products (supplements, dairy products, chocolate, spices). Progress is being made on measures to add more value to the businesses such as expanding sales through e-commerce.

The Nutrition Solutions Unit recorded lower sales and profits than previous year.





Feature: **KANEKA** thinks “Wellness First”. Solutions to Three Crises

Theme of
this Report
Wellness

Kaneka will concentrate its technologies to provide solutions to global threats

The Company has identified three key areas where it can contribute to global crises: “Environment/Energy,” “Food,” and “Wellness.” In this feature, we pick up on the theme of Wellness to introduce a range of solutions for COVID-19.

Response to Urgent Global Measures to Prevent Infection

There is still no clear end in sight to the current COVID-19 pandemic. However, the Company has actively moved to supply PCR testing reagents and active pharmaceutical ingredients (APIs) for Avigan® Tablet since the virus started spreading.

In August 2020, we participated in a manufacturing system for mass production of a DNA vaccine*1 being developed by AnGes, Inc. and Osaka University. Our Group company, Kaneka Eurogentec S.A., has received a contract for production of vaccine intermediates. Kaneka Eurogentec S.A. has high level cutting-edge technologies such as mRNA*2 and plasmid DNA*3



The biomedical contract development manufacturing site of Kaneka Eurogentec S.A.

and continues to handle a surge of inquiries for contracted production of COVID-19 vaccine, the development of which has been accelerated by pharmaceutical companies and bioventures.

In addition, in October 2020, our domestic Group company, Kaneka Medix Corporation (Headquarters: City of Osaka; President: Shozo Ishizaka), started sales of an RT-q PCR kit (product name: KANEKA Direct RT- q PCR Kit “SARS-CoV-2”), able to detect COVID-19 within one hour to medical and testing institutions.

With this newly launched testing kit, pre-treatment is completed by heat treatment only, as there is no need to purify RNA*4 from the virus using samples taken from saliva or the top of the throat. Accordingly, the pretreatment that with conventional methods took around one hour is reduced to around 5 minutes, allowing the overall time needed for the PCR test to be greatly reduced to within an hour.



PCR testing kit that can detect COVID-19 within one hour

The Company implements ESG management and aims for the goal of “Wellness First” to make the world healthy. We have identified three areas in which we can contribute to solutions for global crises as “Environment/Energy,” “Food,” and “Wellness.”

Three Crises

Environment / Energy

Food

Wellness

Contributing to the Prevention of Infection among Medical and Food Workers

The current COVID-19 pandemic has created social issues not only for those infected, but also in terms of preventing infection among workers, such as frontline medical staff.

Demand for ultra-thin gloves to prevent COVID-19 infection has been growing rapidly around the world, mainly for people working in medicine and food industries. In Japan, limited availability has caused prices to soar.

In this environment, the Company has continued to provide a stable supply of Paste PVC, which is a material for hygienic gloves. In this way, we are meeting expanding demand and contributing to infection prevention and hygiene countermeasures.



Ultra-thin gloves made from Paste PVC, used by medical professionals and others

Providing Optimal Solutions through Cross-organizational Systems

The Company aims to make optimal use of its diverse technologies to promote unique social applications in a wide range of fields. To this end, we have established an in-house Infection Research Team to promote R&D into infection countermeasures.

Kaneka is taking a wide range of measures to help solve the coronavirus crisis, including the PCR test kit, the PCR reagents, the manufacturing of a DNA vaccine intermediate, the supplying

of active pharmaceutical ingredients for Avigan® Tablet.

Looking ahead, the Company will bring together its various technologies to assist patients and relevant staff, providing various solutions such as innovative treatments that allow people to spend their healthy, safe and secure lives. In doing so, we will make the entire world healthier.

Sustainable Solutions for an Evolving World.

*1 A vaccine whereby introducing into the body plasmid DNA encoded with proteins from a part of the targeted pathogens (without using any dangerous pathogens), the proteins are produced within the body, giving immunity against said pathogens.

*2 An RNA molecule that is transcribed genetic information of protein synthesis from DNA. It is expected to be used as vaccines and therapeutics.

*3 A general term for circular DNA molecules that exist outside the nucleus of bacteria such as E. coli and yeast, and that are passed down to daughter cells through cell division.

*4 Refers to the genes characteristic of the new coronavirus. Through PCR testing, RNA viruses are amplified to detect infection.

TOPICS 1

Nutrition Solutions Unit

Strengthening the Development of High Value Added Dairy Products
—Aiming to Combine Delicious Flavors with Health

Development of dairy products

The Company entered the dairy product business in 2018. We have been selling and extending our range of dairy products, including the popular “Milk for Bread Lovers” series, as well as “Belgian Yogurt Pur Natur,” a collaboration product made with our technical tie-up partner Pur Natur Invest BVBA of Belgium, and “Pur Natur Fermented Butter.” These products have earned a high



The highly-rated “Milk for Bread Lovers” series

reputation in the market and we continue to expand sales outlets such as convenience stores and supermarkets in addition to our bakery store channel.

In addition, in the near future we plan to launch a new milk tea product in the “Milk for Bread Lovers” series, and a health-conscious yogurt with the



Pur Natur Fermented Butter, with a rich aroma and milky feel

Establishment of an Organic Dairy Farming Company


In June 2020, together with Betsukai Milk World Co., Ltd. (Location: Betsukai-cho, Notsuke District, Hokkaido; President: Sadayuki Nakayama), we established Betsukai Wellness Farm Co., Ltd., a company that will manufacture and sell organic raw milk*1. As an exclusively organic farm, Betsukai Wellness Farm will engage in highly productive organic dairy farming. Betsukai Wellness Farm’s organic farm will go into operation in April 2021, and by 2022 we are aiming to acquire the organic JAS certification*2 in regard to raw milk. The raw milk on this farm will be fully purchased by Kaneka and will be used to expand our product line up to such organic dairy products as milk, butter and in particular yoghurt.

Japan’s dairy farming industry is currently under harsh conditions. Our philosophy is to work with dairy farmers to consider attractive dairy farming and promote sustainable and circular dairy farming that takes into consideration people, cows, and the environment.

- *1 Raw milk taken from cows that have been raised in an environment that conforms to the standards of the organic JAS certification, which involves using organic feed among other practices. Raw milk taken as is from cows and not subjected to processing and is a raw material for milk and dairy products.
- *2 An organic food inspection certification system prescribed by the Ministry of Agriculture, Forestry and Fisheries. It certifies agricultural and livestock products that are produced without reliance on chemical substances such as pesticides or chemical fertilizers.



An image of the new cow barn planned for construction on the organic dairy farm



Location of the organic dairy farming base, Betsukai Wellness Farm Co., Ltd.

TOPICS 2

Health Care Solutions Unit

Contributing to Better Quality of Life with Innovative Medical Technology
—Increase in Medical Catheter Production Capacity and Development of Adsorption Type Plasma Purification Device

Production Capacity in Vietnam Increased

In Japan and Vietnam, Kaneka manufactures medical catheters such as endovascular treatment catheters for cardiovascular, peripheral vascular, cerebrovascular disease, gastroenterology intervention for the treatment of gastrointestinal cancer*1 and electrode catheter for irregular pulse test.



medical catheters

In order to meet strong and growing global demand, Kaneka decided in June 2020 to increase the medical catheter production capacity of Group subsidiary Kaneka Medical Vietnam Co., Ltd. (Headquarters: Binh Duong, Vietnam; President: Toshiyuki Mori). It will build a new plant adjacent to its existing plant, roughly tripling its production capacity. The new plant is scheduled to go into operation from January 2022.



Image of the new factory that will be built to increase production capacity

Populations are aging, especially in developed countries, and the number of patients suffering from cardiac disease, cerebral disorders, and cancer is rising. Surgery using medical catheters is a minimally invasive treatment approach*2 that places less stress on patients, so the global market is expected to grow. With this increase in production capacity, Kaneka will continue to actively launch new products.

Development of a new Adsorption Type Blood Purification Device

The Company has developed an adsorption type blood purification device for treating a severe form of arteriosclerosis obliterans (ASO) with ulcers*3 (Product name: Rheocarna™) and acquired approval for its manufacture and sales in August 2020 with a view to starting sales in spring of 2021.

Due to the growing aging population and increasing diabetes and chronic renal failure, which lead to the most severe form, ASO patients are predicted to increase. The adsorption type blood purification device developed by Kaneka works by selectively removing substances causing ASO symptoms and returns purified blood to the body. This is now possible thanks to the development of novel cellulose beads that adsorb the substances.

Looking ahead, Kaneka will provide solutions that contributed to minimally invasive treatments and blood purification treatments, thereby helping to improve patients’ quality of life.



The adsorption type blood purification device (product name: Rheocarna™)

- *1 Cancer occurring in the gastrointestinal system, including the esophagus, stomach, small intestine, and large intestine
- *2 Treatments that place less stress on the body compared to surgical treatments such as cranial or abdominal surgery
- *3 A disease that causes arteriosclerosis where stenosis and occlusion of lower limbs artery occurred, leading to impaired blood flow (ischemia).

Supporting Agricultural Production by Accelerating Research and Development into Crop Breeding Based on Genome Editing


Kaneka Corporation has signed an agreement with Japan Tobacco Inc. (“JT”) to acquire JT’s assets related to plant biotechnology*1 in August 2020.

The objective of this asset acquisition is to significantly accelerate research and development of crop genome editing and to innovate conventional crop breeding, by taking advantage of Kaneka’s core technology “In planta Genome Editing Technology”*2 (iPB method), which is highly efficient and applicable to a wide range of commercial crop varieties, and JT’s state-of-the-art research facilities, global network with Ag-bio industry and cutting-edge gene delivery technology.

Hereafter, we will accelerate research and development in a

new organization, strengthen license business of gene engineering technology to seed companies, and conduct research and development*3 of crop varieties with beneficial agronomic traits like functionality and high yields under contract with seed companies. Our future targets include seed business of genome-edited crop varieties, which is expected to grow rapidly.

Guided by its principle of “KANEKA Thinks Wellness First,” Kaneka will utilize open innovation to accelerate provision of solutions of various global food problems, such as safe, secure, stable food supply.



*1 Breeding technology to introduce beneficial traits such as disease resistance into plants (tissue culture technology, gene delivery technology, etc.)
 *2 Technology for rapid crop breeding that enables gene modification without integrating the gene cassettes of genome editing technology into the plant chromosomes.
 *3 Developing genome editing seed for requests from customers.

▶ Quarterly Consolidated Balance Sheets (Summary) (Billions of Yen)

Accounts title	97th	96th
	As of September 30, 2020	As of March 31, 2020
Assets		
Current assets	292.0	306.9
Noncurrent assets	352.3	346.4
Total assets	644.3	653.3
Liabilities		
Current liabilities	206.1	211.6
Noncurrent liabilities	81.0	87.6
Total Liabilities	287.1	299.2
Net assets		
Shareholders' equity	332.1	332.7
Others	25.1	21.4
Total net assets	357.2	354.1
Total liabilities and net assets	644.3	653.3

Points

- **Total assets** were ¥644.3 billion as of September 30, 2020, down ¥9.0 billion compared with March 31, 2020, due to a decrease in notes and accounts receivable-trade.
- **Liabilities** totaled ¥287.1 billion as of September 30, 2020, down ¥12.1 billion compared with March 31, 2020, due to a decrease in notes and accounts payable-trade.
- **Net assets** were ¥357.2 billion as of September 30, 2020, up ¥3.1 billion compared with March 31, 2020, due to an increase in valuation difference on available-for-sale securities.

▶ Quarterly Consolidated Statement of Income (Summary) (Billions of Yen)

Accounts title	97th	96th
	From April 1, 2020 to September 30, 2020	From April 1, 2019 to September 30, 2019
Net sales	266.7	299.9
Operating income	7.0	12.8
Ordinary income	4.0	9.7
Income before income taxes	3.9	9.1
Net income attributable to owners of parent	2.5	6.0

Points

- **Net sales** decreased by ¥33.1 billion, or 11.1%, year on year.
- **Operating income** decreased by ¥5.8 billion, or 45.1%, year on year.
- **Ordinary income** decreased by ¥5.7 billion, or 58.5%, year on year.
- **Net income attributable to owners of parent** decreased by ¥3.6 billion, or 59.0%, year on year.

▶ Quarterly Consolidated Statement of Cash Flows (Summary) (Billions of Yen)

Accounts title	97th	96th
	From April 1, 2020 to September 30, 2020	From April 1, 2019 to September 30, 2019
Net cash provided by (used in) operating activities	28.2	16.2
Net cash provided by (used in) investing activities	△ 22.8	△ 20.9
Net cash provided by (used in) financing activities	△ 3.0	△ 3.3
Cash and cash equivalents at end of period	39.9	31.8

Points

- Net cash provided by **operating activities** was ¥28.2 billion, mainly due to income before income taxes and depreciation and amortization.
- Net cash used in **investing activities** amounted to ¥22.8 billion, mainly due to the purchase of property, plant and equipment.
- Net cash used in **financing activities** was ¥3.0 billion, mainly owing to cash dividends paid.
- As a result, **cash and cash equivalents as of September 30, 2020** totaled ¥39.9 billion.

* If you would like to find out more, please visit Kaneka’s website.

Corporate Data

(As of September 30, 2020)

▶ Corporate Profile

Name KANEKA CORPORATION
Tokyo Head Office 1-12-32, Akasaka, Minato-ku, Tokyo 107-6028, Japan
 TEL: +81-3-5574-8000
Osaka Head Office 2-3-18, Nakanoshima, Kita-ku, Osaka 530-8288, Japan
 TEL: +81-6-6226-5050
Date of Establishment September 1, 1949
Paid-in Capital 33,046 million yen
Website <https://www.kaneka.co.jp/en/>

▶ Members of the Board and Audit & Supervisory Board members

Chairman of the Board Kimikazu Sugawara
President Minoru Tanaka
Executive Vice President Kazuhiko Fujii
Member of the Board, Senior Managing Executive Officer Shinichiro Kametaka
Member of the Board, Senior Managing Executive Officer Shinobu Ishihara
Member of the Board, Managing Executive Officer Katsunobu Doro
Member of the Board, Managing Executive Officer Jun Enoki
Member of the Board, Senior Managing Corporate Executive Officer Mamoru Kadokura
Independent Member of the Board Takeo Inokuchi
Independent Member of the Board Mamoru Mohri
Independent Member of the Board Takao Kusakari
Independent Member of the Board Jun Yokota
Audit & Supervisory Board member (standing) Hideyuki Matsui
Audit & Supervisory Board member (standing) Masami Kishine
Audit & Supervisory Board member (outside) Hiroshi Fujiwara
Audit & Supervisory Board member (outside) Yasuhiro Uozumi

▶ Stock Information


Total number of authorized shares150,000,000 shares
 Number of Shares Issued and Outstanding68,000,000 shares
 Number of shareholders22,976 shareholders
 Average number of shares per shareholder2,960 shares

▶ Major Shareholders

Name of Shareholders	Share Units Owned(thousand shares)	Percentage of Total Shares Issued(%)
The Master Trust Bank of Japan, Ltd.(Trust Account)	4,444	6.81
Custody Bank of Japan, Ltd. (Trust Account)	3,986	6.11
Nippon Life Insurance Company	3,114	4.77
Sumitomo Mitsui Banking Corporation	3,091	4.74
Meiji Yasuda Life Insurance Company	2,825	4.33
Custody Bank of Japan, Ltd. (Trust Account No.4)	2,673	4.10
MUFG Bank, Ltd.	2,308	3.54
Mitsui Sumitomo Insurance Company, Limited	2,104	3.23
BNYMSANV AS AGENT/CLIENTS LUX UCITS NON TREATY 1	1,470	2.25
Kaneka Business Partner Shareholding Association	1,154	1.77

Notes : 1. The numbers of Share Units Owned are rounded down to thousands of shares.
 2. The Percentage of Total Shares Issued is calculated by using deducting number of treasury shares from Number of Shares Issued and Outstanding and rounded to two decimal places.
 3. In addition to the above list, the Company maintains 2,762 thousand shares of treasury stock.
 4. Japan Trustee Services Bank, Ltd. changed its name to Custody Bank of Japan, Ltd. on July 27, 2020.

▶ Shareholder Composition



Notes : 1. The numbers of Share Units Owned are rounded down to thousand of shares.
 2. The numbers of Percentage are rounded to one decimal places.

Information for Shareholders



▶ Kaneka's Website

Kaneka's website provides clear, easy to use information to stakeholders such as shareholders and investors. We will continue to enhance the content of the website and to provide timely, appropriate disclosure.




<https://www.kaneka.co.jp/en/>

▼ Top Page



◀ IR Information

The website contains information such as management policy, business performance and financial information, IR materials, and stock information.



Material from the presentation meeting for the new medium-term management plan held on October 5 is also provided.

▶ Memo for shareholders

Fiscal Year	April 1 to March 31
Ordinary Shareholders Meeting	Held in June
Record Dates	Ordinary Shareholders Meeting : March 31 Year-end dividend : March 31 Interim dividend : September 30
Transfer agent and share registrar and account management institution for special accounts	Mitsubishi UFJ Trust and Banking Corporation

- Notes : 1. Procedures such as changes of shareholder's address, requests to acquire shares, and so forth, are to be handled in principle by the account managing institution (securities company, etc.) where the shareholder has an account. Please refer such requests to the securities company, etc., where you have opened an account.
2. For related to shares registered in special accounts, please inquire to the special account managing institution on the left, Mitsubishi UFJ Trust and Banking Corporation. Such enquiries can be received at Mitsubishi Trust and Banking Corporation Head Office and branches.
3. Unclaimed dividends will be paid at the Mitsubishi UFJ Trust and Banking Head Office and branches.

Cover art illustration: Asae Soya
 • Title: Sora
 • Creation date: 2013